Name: I tend to prefer Cosentyx and Tremfya since they have the joint indication. Do you think these are coming for the other drugs in these classes?
Uploaded: 2022-04-28T00:00:00.000Z
Description: I tend to prefer Cosentyx and Tremfya since they have the joint indication. Do you think these are coming for the other drugs in these classes?

Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

I tend to prefer Cosentyx and Tremfya since they have the joint indication. Do you think these are coming for the other drugs in these classes?

Psoriasis

You. So as a rheumatologist, I always advocate for biologics to have both an approval for psoriasis and for psoriatic arthritis. Just because we have a third of our psoriasis patients that will have psoriatic arthritis and it's frequently undiagnosed, or there's a delay in diagnosing, which sort of translates to quality of life being affected for these patients that end up having or developing PSA. So definitely having biologics that work for psoriasis, they should also be approved for psoriatic arthritis if clinical trials suggest efficacy. The fact that cosentic stals are both approved for psoriatic arthritis and tremfia, which is an aisle 23 blocker, got approved for psoriatic arthritis last year, makes me think that the other aisle, twenty three s and the newer IL seven teens that are being investigated will eventually have approval for both psoriasis and psoriatic arthritis.

I tend to prefer Cosentyx and Tremfya since they have the joint indication. Do you think these are coming for the other drugs in these classes?

Related CME